Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related ...

The German Institute for Quality and Efficiency in Health Care (IQWiG) analysed additional data on drugs from the group of gliptins. The drug manufacturers had subsequently submitted these data to the ...

NSCLC showed the largest reduction in metastatic progression with GLP-1RAs versus gliptins (HR 0.50), with significant ...

Gliptins should be used more widely in patients with diabetes as they are associated with less weight gain and fewer hypoglycaemic episodes than sulfonylureas, say researchers. In findings that could ...